Health Care · Pharmaceutical Preparations

LKFT Lakefront Biotherapeutics NV SEC Filings & Insider Trading Activity 2026

company
CIK 142187658 filings

LKFT at a glance

Lakefront Biotherapeutics NV (LKFT, SEC CIK 1421876) filed its latest 20-F annual report on March 26, 2026 and a 6-K report on November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 16 institutional investment managers tracked by SignalX reported holding Lakefront Biotherapeutics NV (LKFT) shares worth $555.9 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
16 funds
$555.9M · −1 vs prior quarter
Latest 6-K
Nov 18, 2026
Foreign issuer report

SignalX for LKFT

Don't miss the next LKFT filing

  • Alerts as it files. A push when LKFT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LKFT, by share count.
  • Ask anything. An AI agent that reads every LKFT filing and answers with sources.

LKFT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LKFT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LKFT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202616$555.9M
Q2 202617$580.3M
Q1 202617$579.9M
Q4 202516$648.2M
Q3 202516$672.8M
Q2 202515$548.1M
Q1 202513$475.7M
Q4 20248$518.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 118 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

Latest 2026 SEC Filings: 20-F, 6-K

FormFiling dateAnalysisSEC
6-KNov 18, 2026--
6-KNov 16, 2026--
6-KNov 12, 2026--
6-KNov 12, 2026--
6-KNov 4, 2026--
6-KNov 2, 2026--
6-KOct 20, 2026--
6-KOct 15, 2026--
6-KOct 13, 2026--
6-KOct 9, 2026--
6-KOct 6, 2026--
6-KSep 29, 2026--
6-KSep 23, 2026--
6-KSep 15, 2026--
6-KSep 8, 2026--
6-KSep 8, 2026--
6-KSep 1, 2026--
6-KAug 25, 2026--
6-KAug 25, 2026--
6-KAug 25, 2026--
6-KAug 18, 2026--
6-KAug 12, 2026--
6-KAug 12, 2026--
6-KAug 4, 2026--
6-KJul 28, 2026--

Related Health Care companies

All Health Care →

LKFT SEC filings: frequently asked questions

Which institutions hold LKFT stock?

As of September 30, 2026, the largest Lakefront Biotherapeutics NV (LKFT) holders among the 13F filers tracked by SignalX were Gilead Sciences ($501.3 million), Renaissance Technologies LLC ($12.6 million), BlackRock ($11.7 million), D.E. Shaw & Co ($9.7 million), Citadel Advisors LLC ($9.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the latest LKFT SEC filings?

Lakefront Biotherapeutics NV (LKFT) filed its latest 20-F annual report on March 26, 2026 and a 6-K report on November 18, 2026.

What is LKFT's SEC CIK number?

Lakefront Biotherapeutics NV (LKFT)'s SEC Central Index Key (CIK) is 1421876. EDGAR lists every LKFT filing under that number.

Ask anything about LKFT

The research agent reads LKFT's filings, financials, insider trades and 13F holders, then answers with sources.